Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular devolution in chronic myelomonocytic leukemia during treatment with decitabine/cedazuridine: A case report.

Annals of hematology - 4 Feb 2026

Geissler Klaus, Mitterbauer-Hohendanner Gerlinde, Jäger Roland

Abstract excerpt

Oral decitabine/cedazuridine has been studied in chronic myelomonocytic leukemia (CMML) recently but the molecular changes during this treatment have not been reported so far. We report a CMML patient who was treated with oral decitabine/cedazuridine and showed a stepwise loss of KRAS mutation and trisomy 8 while the TET2 mutated clone gradually increased eventually resulting in clonal hematopoiesis. This case...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Chromosomes, Human, Pair 8

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clonal Hematopoiesis

Share to Decitabine

Share to Dioxygenases

Share to Leukemia, Myelomonocytic, Chronic

Share to Trisomy

Share to Uridine

Source

Open in PubMed Open full text

Identifiers

PMID: 41634435
DOI: 10.1007/s00277-026-06850-3
PMCID: PMC12868106

Genes

KRAS
TET2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular devolution in chronic myelomonocytic leukemia during treatment with decitabine/cedazuridine: A case report.PMID 41634435Read ↗

Chronic myelomonocytic leukemia with double-mutations in DNMT3A and FLT3-ITD treated with decitabine and sorafenib.Semantic proximity Read ↗

Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemiaSemantic proximity Read ↗

Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia.Semantic proximity Read ↗

Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.Semantic proximity Read ↗

Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy.Semantic proximity Read ↗

Venetoclax is effective for chronic myelomonocytic leukemia blastic transformation with RUNX1 mutation.Semantic proximity Read ↗

The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemiaSemantic proximity Read ↗

Evolution of decitabine developmentSemantic proximity Read ↗

Decitabine and its role in the treatment of hematopoietic malignanciesSemantic proximity Read ↗

Decitabine combined regimen in the therapy of Blastic plasmacytoid dendritic cell neoplasm: case reportSemantic proximity Read ↗

Lineage Conversion in Pediatric B-Cell Precursor Acute Leukemia under Blinatumomab TherapySemantic proximity Read ↗

Mutations in genes affecting DNA methylation enhances responses to decitabine in patients with myelodysplastic syndrome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.